Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world Clinical Patterns Of Care And Outcomes Among Patients In Africa Middle East (Afme) With Metastatic Renal Cell Carcinoma (Mrcc) Receiving Sunitinib As First Line Therapy. Prospective Primary Data Collection Study

Trial Profile

Real-world Clinical Patterns Of Care And Outcomes Among Patients In Africa Middle East (Afme) With Metastatic Renal Cell Carcinoma (Mrcc) Receiving Sunitinib As First Line Therapy. Prospective Primary Data Collection Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms OPTIMISE
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jun 2017 Planned initiation date changed from 24 May 2017 to 30 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top